Skip to content

Septerna, Inc. SEPN Discovery Research Milestones — Transaction Price

Similar metrics at other companies

BioCryst Pharmaceuticals logo
BCRXResearch and Development — Contract with customer, transaction price
$20.67M
Zymeworks logo
ZYMEResearch Milestone — Research and development collaborations (note 11)
$8.75M
Zymeworks logo
ZYMEResearch, Development and Commercial Milestones — Research and development collaborations (note 11)
$0
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%
Zymeworks logo
ZYMECommercial and Development Milestones — Research and development collaborations (note 11)
$0
Zymeworks logo
ZYMEMilestone revenue — Research and development collaborations
$0-100%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept sepn:TransactionPrice.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s discovery research milestones — transaction price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s discovery research milestones — transaction price?
Septerna, Inc. (SEPN) reported discovery research milestones — transaction price of $2M in Q1 2026.
What does discovery research milestones — transaction price mean?
This metric represents the total transaction price allocated to performance obligations related to discovery research milestones within a collaborative or licensing agreement. It reflects the aggregate consideration expected to be received by the company upon the successful achievement of specific research-based technical or scientific objectives. This figure provides insight into the potential value captured from early-stage drug discovery partnerships.